Anticoagulation Therapy News @ ESC Congress 2019

Latest insights and scientific developments from the European Society of Cardiology Congress 2019

Well it’s all over for another year but we have a fabulous 3-part round-up on some of the key take home messages from the ESC Congress 2019 (see below list).
You can also still check out the blogs for the rest of the week including; ‘Day 1: Atrial fibrillation – Where are we now and what does the future hold?’ exploring how to prevent adverse outcomes in AF and there’s also ‘Day 2: Improving outcomes for patients with atrial fibrillation’, featuring the new real-world data for apixaban from the NAXOS study, Day 3: Optimising AF Management and Utilising Technology and Day 4: Focus on patients with AF undergoing PCI.

  • Round-up of the ESC Congress 2019 | Part 3

    Our final round-up from the Congress details integrated care vs. routine care, raising important questions in the management of atrial fibrillation.

  • Round-up of the ESC Congress 2019 | Part 2

    Our round-up takes a bitesize look at the importance of understanding all the facts around atrial fibrillation, centred on four principles which every healthcare professional should alert themselves to when a patient presents with symptoms of AF.

  • Round-up of the ESC Congress 2019 | Part 1

    If you’ve missed any of the coverage from ESC Congress 2019 our blog is a great way to catch up with key news and insights. Discover more about the hot topics this year including the rise of digital initiatives, key anticoagulation data and why we must adopt a more holistic approach in AF.

  • Day 4 - Focus on patients with AF undergoing PCI

    What challenges are there in the current treatment landscape in patients with atrial fibrillation undergoing percutaneous intervention? With the release of new data for this high-risk population where do we stand now?

  • Day 3 - Optimising AF Management and Utilising Technology

    There was a strong digital focus at today’s ESC Congress 2019, with late breaking science reporting advances in AF screening. Day 3 also saw great discussions surrounding clinical management, particularly the use of DOACs to optimise management in high-risk patients with AF and acute coronary syndrome/percutaneous intervention.

  • Day 2 - Improving outcomes for patients with atrial fibrillation

    Find out all about the NAXOS real-world data and discover more about stroke prevention in atrial fibrillation. What new evidence is there on DOACs?

  • Day 1 - Atrial fibrillation – Where are we now and what does the future hold?

    Find out about the latest digital technology and discover more about preventing adverse outcomes in atrial fibrillation.

  • The epgonline.org team attended and reported back from ESC 2019, held in Paris, France between 31 August and 4 September looking at some of the most exciting developments in anticoagulant therapies and stroke prevention.

    This year, the ESC Congress was held together with the World Congress of Cardiology to focus on Global Cardiovascular Health. The five-day conference highlighted differences in prevalence, diagnosis, prevalence and management of cardiovascular disease. It was a key event not to be missed and you can read all about it here at epgonline.org.

    We have published daily reports covering the latest scientific and clinical advances in cardiology, including late-breaking data. These highlights are of the best and latest science as presented by leading experts at ESC 2019. They have also been developed independently of the sponsors who have had no editorial input into the content.

    As well as the latest happenings from ESC 2019, you may also be interested in other topics within this learning zone including the epidemiology of stroke, the pathophysiology of atrial fibrillation and European treatment recommendations for patients with atrial fibrillation.

Login/ Register Maximise Minimise